Trial Profile
Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 12 Mar 2021 Planned End Date changed from 30 Sep 2021 to 31 Dec 2021.
- 12 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.
- 12 Mar 2021 Status changed from active, no longer recruiting to recruiting.